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Abstract
Recently, the term MSCRAMM (microbial surface components recognizing adhesive matrix molecules), has been
introduced to describe microbial molecules that recognize extracellular matrix (ECM) [1]. Here we present evidence for the
presence of fibronectin-binding molecules in Borrelia burgdorferi and several other Borrelia species. Immunofluorescence
studies show that plasma fibronectin is bound uniformly over the cell surface of free swimming B. burgdorferi. In addition,
the spirochetes are able to bind to plasma fibronectin-coated microwell plates, an interaction that is inhibited by anti-
fibronectin antibody as well as exogenous plasma fibronectin. Taken together, the data suggest that fibronectin binds to the
surface of the spirochete. On Western blot-like assays, B. burgdorferi and some B. afzelii strains express a major fibronectin-
binding protein (Fn-BA) with an approximate molecular mass of 52 kDa. In addition, several other major Fn-BAs were
found in B. hermsii (26, 31, 33, 39, 46, 54 and 58 kDa) and B. turicatae (39, 41, 45, 50, 56, 59 and 66 kDa). Preliminary
evidence suggests that fibronectin (and Fn-BA) may play a role as a molecular bridge between the spirochete and other
components of the extracellular matrix. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Lyme disease is the most frequently reported ar-
thropod-borne infection in North America and Eu-
rope [2] and accounts for over 80% of all vector-
borne infections in the United States [3]. Lyme dis-
ease is a multisystem disorder in humans and other
mammals caused by the spirochete Borrelia burgdor-
feri [4]. Recently, the term MSCRAMM (microbial
surface components recognizing adhesive matrix
molecules) has been introduced to describe microbial
molecules that recognize extracellular matrix (ECM)
components including heparin-related polysaccha-
rides, ¢brinogen, collagen and ¢bronectin [1]. It is
well known that B. burgdorferi adheres to many dif-
ferent mammalian cell types and has a predilection
for components of the ECM, such as collagen [5^7]
and ¢bronectin [8]. Guo et al. [9] have shown that
binding of B. burgdorferi to dermal collagen may be
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mediated via interactions of spirochete-speci¢c de-
corin-binding proteins. In addition, it has been dem-
onstrated that B. burgdorferi binding to ECM com-
ponents is inhibited by anti-¢bronectin antibodies [8].
The presence of potential ¢bronectin binding pro-
teins on the cell membrane of B. burgdorferi has
also been inferred from the recently published ge-
nomic sequence [10]. Taken together, the data sug-
gest the presence of multiple MSCRAMMs in B.
burgdorferi. As a consequence of these ¢ndings, and
because of the multiple binding speci¢cities of ¢bro-
nectins, we have investigated and now report on the
¢bronectin-binding (¢bronectin-MSCRAMM) activ-
ities in B. burgdorferi.
2. Materials and methods
2.1. Materials
Rabbit serum was obtained from Pel-Freeze Bio-
logicals (Rogers, AR). All reagents used for SDS-
PAGE were from Bio-Rad Laboratories (Hercules,
CA). Vectastain ABC Kit was from Vector Labora-
tories (Burlingame, CA). High binding, £at bottom
EIA/RIA microwell plates were obtained from Co-
star Corporation (3590) (Cambridge, MA). Sheep
anti-human ¢bronectin IgG and sheep anti-rabbit
¢bronectin IgG were from The Binding Site (San
Diego, CA), and normal sheep IgG was from Sigma
(St. Louis, MO). Highly puri¢ed human plasma ¢-
bronectin (s 95%) was obtained for Boehringer-
Mannheim (Indianapolis, IN). Trans-35S-Label met-
abolic labeling reagent was from ICN, Costa Mesa,
CA. Gelatin-free BSK H medium, dextran sulfate,
and all other biochemicals were from Sigma (St.
Louis, MO).
2.2. In vitro cultivation of spirochetes
Low passage (6 10) B. burgdorferi strains JD1,
CA20 and N40, were obtained from the Centers of
Disease Control (CDC). Low passage B. burgdorferi
(strains HB19-lp and CA-1-87), B. afzelii (strains J1,
P. Gau, and ACA-1), B. garinii (strains NBS16, G25
and G1), B. turicatae, as well as high passage (s 50)
B. burgdorferi strains, HB19-hp, and B. hermsii-hp
(s 100) were obtained from Dr. D. Thomas (Univer-
sity of Texas Health Science Center at San Antonio).
B. burgdorferi M297, an OspA and OspB de¢cient
mutant strain of 297, originally obtained from the
heart of a hamster [11], was obtained from Dr. Rus-
sell Johnson (University of Minnesota). Low passage
B. burgdorferi strain JD1 is pathogenic in monkeys
[12,13] and B. burgdorferi strain HB19-lp, B. garinii
strains G1 and ACA-1, and T. turicatae have been
tested in mice and are infectious, whereas, B. hermsii
is serotype C and is non-infectious (D. Thomas; per-
sonal communication). B. burgdorferi 20515 targets
to dermal connective tissues [14] and strain M297 is
non-infectious, at least in hamsters [11]. All other
low passage B. burgdorferi strains (CA20, N40,
CA-1-87) are infectious, while high passage spiro-
chete strains (B. burgdorferi HB19-hp and B. hermsii)
are not.
The spirochetes were cultured at 34‡C (in 5% CO2,
3% 02 and 92% N2) in gelatin-free BSK H medium
containing 10% young-rabbit serum according to
Barbour [15]. For use in protein-coated microwell
plate binding assays, B. burgdorferi, initially seeded
at 3U107/ml, were metabolically labeled in BSK-H
medium supplemented with [35S]methionine and
[35S]cysteine (10 mCi/ml; as Trans-35S-Label) for
24^48 h. The bacteria were centrifuged 4000Ug for
10 min and washed twice in phosphate-bu¡ered sa-
line, pH 7.6, containing 0.5% (w/v) BSA and 0.5%
(w/v) glucose (PBS+BG). The radiolabeled spiro-
chetes were resuspended in PBS+BG wash bu¡er
and examined under a dark-¢eld microscope to verify
that the organisms were thoroughly dispersed at the
start of all assays.
2.3. Fractionation of human plasma
Human plasma was prepared from citrated blood
using standard procedures. Plasma (0.5 ml) was in-
jected into a 10U300 mm BioSep 4000 column
linked in tandem to a 10U300 mm BioSep 2000 col-
umn which was equilibrated in 5 mM sodium citrate
in PBS, pH 7.4 bu¡er. The £ow rate was 2 ml/min.
The fractions were collected (1.0 ml) and assayed for
spirochete adhesion activity as described below.
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2.4. Adhesion assays: B. burgdorferi attachment to
protein-coated microwell plates
Flat-bottom, high binding 96-well microwell plates
were coated overnight (4‡C) with 100 Wl of plasma
¢bronectin or HPLC fractionated plasma samples
(100 Wg/ml PBS). The wells were washed twice with
PBS and then blocked with 250 Wl 5% BSA (in PBS)
for 1 h at 37‡C. The control wells were incubated
with PBS prior to blocking with BSA. Fifty Wl of
radiolabeled B. burgdorferi (107 organisms/well)
were added together with 50 Wl PBS+BG with and
without other additions. The spirochetes were al-
lowed to attach for 2 h at ambient temperature.
After washing the microwell plates 4 times in
PBS+BG, the attached bacteria were solubilized in
100 Wl 1% (w/v) sodium dodecyl sulfate (SDS), and
the released radioactivity counted in a Beckman
liquid scintillation counter. In each experiment, spi-
rochete binding to BSA was always one of the con-
trols.
2.5. Detection of ¢bronectin on B. burgdorferi by
immuno£uorescence microscopy
B. burgdorferi (5U106) in 3 ml of PBS+BG were
spread onto glass microscope slides and allowed to
air-dry before blocking for 15 min with 5% BSA in
PBS. The slides were then washed in PBS containing
0.2% (w/v) BSA. After the addition human plasma
¢bronectin or human serum (20 Wg/ml PBS), or PBS,
the slides were incubated with the sheep anti-human
¢bronectin IgG followed by FITC-labeled anti-sheep
IgG antibody (1 h each with washes in between)
before mounting in PBS containing 10% glycerol.
The slides were examined for epi£uorescence under
UV illumination.
2.6. Identi¢cation of ¢bronectin-binding proteins
Borrelia burgdorferi and other Borrelia sp. whole
cell lysates were subjected to SDS-PAGE under re-
ducing conditions [17] and the ¢bronectin-binding
activities (Fn-BA) determined in a Western blot-
type assay. For SDS-PAGE the spirochetes were
solubilized under reducing conditions in SDS by in-
cubation at 37‡C for 30 min or 100‡C for 5 min.
After electrophoresis, the proteins were electropho-
retically transferred (1 h at 100 V) onto nitrocellulose
membranes. The membranes where blocked with ei-
ther 2% (w/v) dry milk or 1% Tween 20 (v/v) in PBS
for 1 h at ambient temperature, followed by two
washes with PBS. Human plasma ¢bronectin at
5 Wg/ml in PBS in 0.2% milk was added and the blot
was incubated at ambient temperature for 2 h. After
three washes with PBS, the blots were incubated for
2 h (ambient temperature) with sheep anti-human
¢bronectin IgG (diluted 1:1000). The blots were
again washed three times with PBS before incubation
with a biotin-labeled anti-sheep IgG antibody (30
min). After washing, the immune complexes were
incubated with avidin and biotinylated horseradish
peroxidase using the Vectastain ABC system accord-
ing to the manufacturer. The immunoperoxidase
complexes were identi¢ed using 4-chloro-1-naphthol
(1 mg/ml). The blots were scanned on a Pharmacia
LKB ImageMaster UltroScan XL laser densitometer
Fig. 1. The selective binding of B. burgdorferi JD1 to plasma
fractions. Human plasma was partially puri¢ed by gel-permea-
tion HPLC and the fractions immobilized on to microwell
plates as described in Section 2. The ¢gure shows the binding
of radiolabeled B. burgdorferi JD1 to the puri¢ed plasma frac-
tions. The elution of the column calibration standards (Blue
dextran, 2000 kDa; apoferritin, 443 kDa; alcohol dehydrogen-
ase, 150 kDa; carbonic anhydrase, 29 kDa; vitamin B12, 1.355
kDa) are shown by the arrows.
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and the data analyzed using ImageMaster version 1.0
software. Using the Vectastain ABC system, the spe-
ci¢city of the sheep anti-human ¢bronectin IgG was
tested on Western blots and was found to recognize
both puri¢ed human plasma ¢bronectin and proteins
in the 200 kDa region of whole human serum or
plasma. In addition, this antibody cross-reacted
with proteins only in the 200 kDa ¢bronectin region
of whole rabbit serum.
3. Results
3.1. Binding of B. burgdorferi to immobilized
¢bronectin
In early experiments, we assessed the ability of B.
burgdorferi strain JD1 to adhere to HPLC puri¢ed
plasma fractions immobilized on microwell plates
(Fig. 1A). Surprisingly, several peaks of spirochete
Fig. 2. The binding of B. burgdorferi to immobilized ¢bronectin
or BSA. (A) The binding of radiolabeled B. burgdorferi JD1 to
immobilized human ¢bronectin or BSA is represented by the
open bars. The shadowed bar shows the binding of B. burgdor-
feri JD1 to ¢bronectin in the presence of sheep anti-human ¢-
bronectin IgG (5.3 Wg). (B) The binding of radiolabeled B.
burgdorferi M297 to either immobilized human ¢bronectin or
BSA is represented by the open bars. The shadowed bars repre-
sent the binding of B. burgdorferi M297 to either immobilized
¢bronectin or BSA in the presence of human plasma ¢bronectin
(5 Wg). The data in both (A) and (B) are represented as the
mean cpm þ S.D. (n = 3). Fig. 3. The dose-dependent inhibition of B. burgdorferi binding
to immobilized ¢bronectin by anti-¢bronectin IgG. (A^C) The
binding of radiolabeled B. burgdorferi strains JD1 (A), CA20
(B) and N40 (C) to immobilized human ¢bronectin in the pres-
ence of increasing amounts of anti-human ¢bronectin IgG. The
data are represented as the number spirochetes bound in the
presence of antibody relative to controls not containing added
IgG: mean þ S.D. (n = 3). (D) The binding of radiolabeled B.
burgdorferi M297 to immobilized human ¢bronectin in the pres-
ence of increasing amounts of sheep anti-human ¢bronectin
IgG (closed circles), sheep anti-rabbit ¢bronectin IgG (closed
squares), or normal sheep IgG (closed triangles). The data are
represented as the number spirochetes bound in the presence of
antibody relative to controls not containing added IgG:
mean þ S.D, (n = 3).
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binding activity were observed, the major B. burgdor-
feri binding activity being associated with a fraction
with the same molecular mass as plasma ¢bronectin,
at approximately 440 kDa. We, therefore, tested the
ability of several B. burgdorferi strains to adhere to
puri¢ed plasma ¢bronectin (Figs. 2 and 3). For B.
burgdorferi strains M297 and JD1, the binding of
spirochete to immobilized plasma ¢bronectin was
12- and 19-fold greater than the BSA background
and the spirochetes appeared to bind via their tips
Fig. 4. Distribution of ¢bronectin on B. burgdorferi by immuno£uorescence: After washing in PBS+BG, B. burgdorferi strains JD1,
M297 and 20515 were tested for the presence of bound ¢bronectin using sheep anti-¢bronectin antibody followed by FlTC-labeled
anti-sheep: (A) JD1; (B) M297; and (C) 20515. In (D) and (E), B. burgdorferi 20515 was also preincubated with either human plama
¢bronectin (D) or human serum (E) prior to the addition of sheep anti-human ¢bronectin antibody followed by FlTC-labeled anti-
sheep antibody. No £uorescence above background levels was observed when the second FITC-labeled antibody was incubated alone
(F). Similar ¢ndings to those obtained with 20515 (F) were also found for JD1 and M297 (not shown).
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as observed by light microscopy. The presence of
soluble ¢bronectin inhibited this binding by approx-
imately 50% (Fig. 2). In addition, sheep anti-human
¢bronectin IgG caused a dose-dependent inhibition
(v75%) of the binding of several B. burgdorferi
strains (JD1, CA20, N40), including an OspA and
OspB de¢cient mutant (M297), to immobilized ¢bro-
nectin. (Fig. 3A^D). Sheep anti-rabbit ¢bronectin
could also inhibit spirochete binding to human ¢bro-
nectin. Normal sheep IgG had no e¡ect on binding
to ¢bronectin (Fig. 3D). The interference of spiro-
chete adhesion to human ¢bronectin by anti-rabbit
¢bronectin IgG is intriguing. It is possible that the
anti-rabbit IgG prevents spirochete-bound rabbit ¢-
bronectin from directly interacting with the immobi-
lized human ¢bronectin. It is also possible that the
anti-rabbit IgG simply cross-reacts with human ¢-
bronectin. We know, for example, that anti-human
¢bronectin IgG cross-reacts with rabbit ¢bronectin.
Whether either or both scenarios are possible re-
mains to be determined. Fibronectin-coated wells,
which were preincubated with anti-¢bronectin IgG
and then extensively washed to remove unbound
antibody, were unable to support spirochete binding
(not shown).
In conclusion, B. burgdorferi binds to immobi-
lized ¢bronectin, and this interaction is inhibited
by both soluble ¢bronectin or anti-¢bronectin anti-
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body. The ability of B. burgdorferi M297, a mutant
de¢cient in OspA and OspB, to bind to ¢bronectin
suggests that these Osp proteins are not required
in spirochete adhesion to this important ECM pro-
tein.
3.2. Immunolocalization of plasma ¢bronectin in
B. burgdorferi
The ability of human plasma ¢bronectin to bind to
intact B. burgdorferi was assessed by immuno£ou-
resence using anti-¢bronectin IgG. Borrelia burgdor-
feri strains JD1, M297 and 20515, all obtained dur-
ing the late exponential phase of growth, were tested
for the presence of bound plasma ¢bronectin using
sheep anti-human ¢bronectin IgG followed by FlTC-
labeled anti-sheep antibody (Fig. 4). In general, in
the absence of any added ¢bronectin all three strains
exhibited a spectrum of antibody labeling both in
regards to £uorescence intensity as well as in the
number of ¢bronectin positive spirochetes (Fig.
4A^C). This may have been due to ¢bronectin re-
moval as B. burgdorferi and other spirochetes are
known to produce ‘blebs’ of their outer surface
[15,16], as well to varying cross-reactivities between
the anti-human ¢bronectin IgG and rabbit ¢bronec-
tin (presumably obtained from the culture medium).
The cells were also preincubated with either puri¢ed
human plasma ¢bronectin (Fig. 4D) or human serum
(Fig. 4E) prior to the addition of anti-¢bronectin
antibody. In this situation, we observed a pattern
of uniform cell surface £uorescence on all the cells.
In control experiments when only the second FlTC-
labeled antibody was used, no £uorescence above
background levels was observed with any isolate
(Fig. 4F). In conclusion, the data suggest that plasma
¢bronectin uniformly binds over the entire cell sur-
face B. burgdorferi. Again, because B. burgdorferi
strain M297 binds to both soluble (Fig. 4) and im-
mobilized plasma/plasma ¢bronectins (Figs. 2 and 3),
it is unlikely that OspA and OspB act directly as
¢bronectin-binding proteins.
6
Fig. 5. Detection of ¢bronectin-binding activities in B. burgdorferi and other Borrelia species by Western-blot type assay. (A) B. burg-
dorferi strains JD1 and M297 were solubilized in sample bu¡er by incubation at 37‡C for 30 min prior to SDS-PAGE (10% gel) (50
Wg protein/lane) and the proteins electrophoretically transferred on to nitrocellulose membranes. The membranes were probed with
anti-human ¢bronectin IgG preincubated with 0.2% de-fatted milk, with (lanes 1^3) or without (lanes 4^6) human plasma ¢bronectin
(5 Wg/ml). The blots were sequentially incubated with a sheep anti-human ¢bronectin IgG and the immune complexes were incubated
with avidin and biotinylated horseradish peroxidase. The molecular weight markers (112, 84, 53.2, 34.9, 28.7, and 20.5 kDa) are
shown in lanes 1 and 4. B. burgdorferi strains JD1 and M297 are in lanes 2 and 5, and lanes 3 and 6, respectively. The positions of ¢-
bronectin (arrow) and the major Fn-BA (arrowhead) are also shown. (B) B. burgdorferi strain JDl, isolated during di¡erent growth
phases were solubilized in sample bu¡er (30 min 37‡C for 30 min) and subjected to SDS-PAGE (4^20% gradient polyacrylamide gel)
and the proteins electrophoretically transferred onto nitrocellulose membranes. The membranes were probed with anti-¢bronectin IgG
after previous pre-incubation with 0.2% de-fatted milk with (lanes 1^6) or without (lanes 7^13) 5 Wg/ml human plasma ¢bronectin.
The blots were reacted with anti-human ¢bronectin IgG. B. burgdorferi isolated from cultures grown to a cell density of 1U107,
2U107, 4U107, 8U107, and 1.6U108 spirochetes/ml are shown in lanes 2 and 8, 3 and 9, 4 and 10, 5 and 11, and 6 and 12, respec-
tively. Lane 13 was a blank. The prestained molecular weight markers (112, 84, 53.2, 34.9, 28.7, and 20.5 kDa) are in lanes 1 and 7.
The position of the major Fn-BA (arrowhead) is shown. (C) Human plasma ¢bronectin, trypsinized human plasma ¢bronectin and B.
burgdorferi JD1 were fractionated by SDS-PAGE, electrophoretically transferred onto nitrocellulose membranes, and probed with
(lanes 1^5) or without (lanes 6^10) human ¢bronectin after blocking with 1% (v/v) Tween 20. The blots were probed with anti-human
¢bronectin IgG. Lanes 1 and 7, B. burgdorferi JD1 (4U106 organisms) after 3 washes with PBS. Lanes 2 and 8, B. burgdorferi JD1
wash 2U with PBS and 1U with 100 mM Na2C04, pH 11. Lanes 3 and 9, plasma ¢bronectin (3 Wg). Lanes 4 and 10, plasma ¢bro-
nectin (3 Wg) treated with TPCK-treated trypsin (5 Wg). Lanes 5 and 6 contain the molecular weight markers. The arrowhead points
to the position of the major Fn-BA and the double arrows point to the ¢bronectin region on the gel. (D) Several Borrelia species
were solubilized in sample bu¡er by incubation at 100‡C for 5 min. prior to SDS-PAGE (12% gel) (108 spirochetes per lane) and the
proteins electrophoretically transferred onto nitrocellulose membranes. The membranes were probed with anti-¢bronectin IgG after
previous pre-incubation with 0.2% de-fatted milk with 5 Wg/ml human plasma ¢bronectin. The blots were reacted with anti-human ¢-
bronectin IgG. The arrowhead points to the position of the major 52 kDa B. burgdorferi Fn-BA. Lane 1, molecular weight markers,
105, 82, 49, 33.3, 28.6, and 19.4 kDa; lane 2, B. burgdorferi JD1; lane 3, B. burgdorferi HB19-lp; lane 4, B. burgdorferi HB19-hp;
lane 5, B. afzelii J1; lane 6, B. garinii NBS16; lane 7, B. garinii G25; lane 8, B. afzelii ECM-1; lane 9, B. hermsii-hp; lane 10, B. afze-
lii P Gau; lane 11, B. afzelii ACA-1 1p; lane 12, B. burgdorferi CA-1-87; lane 13, B. turicatae ; lane 14, B. garinii G1.
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3.3. The ¢bronectin-binding activities of
B. burgdorferi
We used a Western-like assay to determine what
B. burgdorferi proteins (or other molecules) were re-
sponsible for binding plasma ¢bronectin. As seen
from the ¢bronectin Western-like data in Fig. 5, all
of the B. burgdorferi strains tested (i.e. low passage
JD1, CA-1-87, HB19 and high passage HB19), and
the B. burgdorferi OspA and OspB de¢cient mutant
M297 express an approximately 52 kDa Fn-BA. This
52 kDa molecule is also present in early exponential,
mid-exponential, and stationary-growth phases of
the spirochetes (Fig. 5B). It should be noted that a
small amount of background binding to the 52 kDa
Fn-BA region is seen occasionally in the control
blots blocked with milk only. This background can
be explained by the fact that milk has been shown to
contain small amounts of ¢bronectin [18]. More im-
portantly, this background disappears when the blots
are blocked with Tween-20 (Fig. 5C). Incubation of
the blots with ¢bronectin did not signi¢cantly in-
crease the immunoreactivity of the approximately
200 kDa protein region (presumably due to antibody
cross-reactivity with spirochete-bound rabbit ¢bro-
nectin present in the samples prior to SDS-PAGE).
This suggests that the added plasma ¢bronectin in
the assay does not bind to the ¢bronectin obtained
by the spirochete from the culture medium prior to
denaturation in SDS-PAGE sample bu¡er (Fig. 5C;
also see Fig. 5A). The reaction to the 52 kDa Fn-BA
region was also not due to binding to ¢bronectin
fragments. On Western blots, anti-¢bronectin IgG
strongly recognized bands in the approximately 200
kDa region of puri¢ed plasma ¢bronectin (Fig. 5C).
When probed with anti-¢bronectin IgG blots of tryp-
sin-treated plasma ¢bronectin showed many bands
with molecular weights lower than 110 kDa. Incuba-
tion of the blots with ¢bronectin prior to addition of
the anti-¢bronectin IgG did not signi¢cantly increase
the intensity of the antibody signal to trypsin ¢bro-
nectin fragments (Fig. 5C). Treatment of spirochetes
with highly alkaline bu¡er removes most of the
bound ¢bronectin, but the 52 kDa Fn-BA appears
to be bound fairly tightly to the spirochete mem-
brane because it was resistant to removal under these
conditions (Fig. 5C). In conclusion, under the con-
ditions used, plasma ¢bronectin did not bind either
to itself or proteolytically generated ¢bronectin-de-
rived peptides on nitrocellulose blots.
We also looked for the presence of Fn-BAs in
other Borrelia species including low passage B. afze-
lii, B. garinii, B. turicatae and high passage B. herm-
sii. As seen in Fig. 5D, B. afzelii strains J1, ECM-1,
P Gau, but not B. afzelii ACA-1, were found to
contain varying amounts of Fn-BAs. Recently,
Kopp et al. [19] puri¢ed a 147 kDa ¢bronectin bind-
ing protein in B. garinii strain N34. Although we did
not test strain N34, we were unable to detect any 147
kDa Fn-BA in the B. garinii strains NBS16, G25 or
G1. Furthermore, B. garinii strains tested express
little, if any, of the 52 kDa Fn-BA when compared
to B. burgdorferi. Unlike the relatively simple pat-
terns of ¢bronectin binding displayed by B. burgdor-
feri and B. afzelii, two species of Borrelia known to
cause ‘relapsing fever’, appear to possess several rad-
ically di¡erent molecular weight Fn-BAs from the
major 52 kDa Fn-BA. For example B. hermsii (lane
9) displayed several major ¢bronectin binding activ-
ities between 26 and 58 kDa. In contrast, B. turicatae
(lane 13) showed binding activities with generally
higher relative molecular masses: between 39 and
66 kDa.
4. Discussion
The presence of adhesion molecules on the surface
of microorganisms capable of interacting with the
extracellular matrix of cells is often a crucial ingre-
dient in the modulation of many invasive processes.
It is well known that B. burgdorferi adheres to many
di¡erent mammalian cell types and has a predilection
for components of the ECM such as collagen [5^7],
decorin [9] and ¢bronectin [8]. However, the molec-
ular mechanisms involved in attachment, an event
that is presumably important in the spirochete’s abil-
ity to invade many diverse tissues, remain mostly
unknown. Recently, the term MSCRAMM (Micro-
bial Surface Components Recognizing Adhesive Ma-
trix Molecules) has been introduced to describe mi-
crobial molecules that recognize components of the
ECM including heparin-related polysaccharides, ¢-
brinogen, collagen and ¢bronectin [1]. Fibronectins
are complex high molecular weight glycoproteins
found in mesenchyme cells, in plasma, in the inter-
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stitial extracellular matrix, and in association with
proteoglycans, intregrins and collagen ¢brils [1,20^
25]. As a prototypical-MSCRAMM, ¢bronectin-
binding MSCRAMM has been found in many mi-
croorganisms [1]. Several putative ¢bronectin-bind-
ing MSCRAMMs have been described in Mycobac-
terium spp., Candida albicans, Pneumocystis carinii,
Trypanosoma cruzi, and Leishmania, Treponema pal-
lidum and Treponema denticola [1,26^30]. In this
study, we demonstrate that B. burgdorferi may also
possesses ¢bronectin-binding MSCRAMMs.
Szczepanski and co-workers [8] were the ¢rst to
demonstrate that B. burgdorferi binding to ECM
components could be inhibited by anti-¢bronectin
antibodies [8]. As shown in this study, B. burgdorferi
is able to bind to human plasma ¢bronectin which
had been immobilized onto plastic, an interaction
that was strongly inhibited by both soluble ¢bronec-
tin and anti-human or anti-rabbit ¢bronectin anti-
bodies. The ability of both anti-¢bronectin antibody
and plasma ¢bronectin to inhibit the adherence of
free-swimming B. burgdorferi to these ¢bronectin-
coated plates suggests that ¢bronectin is present on
the surface of the microorganism. Indeed, immuno-
£uorescence studies showed that ¢bronectin was
bound on the surface of free swimming B. burgdor-
feri. A similar cellular distribution has also been
demonstrated for two other closely related spiro-
chetes: T. pallidum [26,27] and T. denticola [28,29].
The binding of B. burgdorferi to ¢bronectin does not
appear to involve binding to OspA or OspB. Re-
cently, the entire genomic sequence of a B. burgdor-
feri spirochete was published by Fraser and co-work-
ers [10]. It is of interest that a gene was identi¢ed
(BB347) which may encode for a cell envelope pro-
tein. BB347 shares a 53.5% similarity to a putative
¢bronectin/¢brinogen binding protein in Streptococ-
cus pyogenes [10]. Based on the peptide sequence
data, we calculate the molecular mass of this putative
¢bronectin/¢brinogen binding protein to be 55.9
kDa, a number which includes the initial methionine
residue. It remains to be seen whether the 52 kDa
¢bronectin binding molecule reported here is derived
from, or otherwise related, to this putative ¢bronec-
tin/¢brinogen binding activity. However, this seems
to be a reasonable proposition.
The major Fn-BA is an approximately 52 kDa,
heat stable molecule, that is present in varying
amounts in several strains of B. burgdorferi and in
all in vitro growth stages (of B. burgdorferi strain
JD1). Because ¢bronectin appears to bind to the sur-
face of the spirochete, we assume that the major Fn-
BA is also associated with some surface component.
The Fn-BA also does not appear to be a proteolytic
¢bronectin fragment. In addition, we have found
similar 52 kDa Fn-BAs in B. afzelii and several other
di¡erent Fn-BAs in Borrelia species known to cause
‘relapsing fever’: B. hermsii and B. turicatae. We do
not as yet understand the nature of these multiple
kDa Fn-BA activities. However, multiple Fn-BAs
(89.5, 37 and 32 kDa) have been described and lo-
calized to the outer envelope of T. pallidum [26,27].
Similarly, in T. denticola major 53 and 72 kDa
[28,29], as well as a minor 45 kDa [28] ¢bronectin
binding proteins have been identi¢ed. The 53 kDa T.
denticola protein has been found to be distributed on
the entire cell surface [28]. In free swimming B. burg-
dorferi spirochetes we also found that ¢bronectin
(and presumably the 52 kDa Fn-BA) covers the en-
tire surface of the cell. However, it is not yet known
whether B. burgdorferi ¢bronectin adhesins cluster
toward the tip after binding to cells or to immobi-
lized ¢bronectin as is the case of T. pallidum [23,24]
and T. denticola [30^32]. Immunological reagents to
the 52 kDa Fn-BA, when available, will help resolve
these important issues. Recently, Guner [33] demon-
strated that ¢bronectin protects B. burgdorferi from
complement mediated lysis. In this scenario, we en-
vision that uniformly bound surface ¢bronectin on
the spirochete surface could function to protect the
bacteria in the circulation. In the process of actively
binding to cells, the spirochetes would recruit Fn-
BAs to their tips, e¡ectively increasing the spirochete
avidity towards ¢bronectin or other host cell mole-
cules at the region of cell binding as has been sug-
gested for T. pallidum [23,34] and for T. denticola
[30^32].
It is of interest that both low passage and patho-
genic and high passage and presumably non-patho-
genic B. burgdorferi HB19 strains contain the 52 kDa
Fn-BA. This Fn-BA is also found in B. burgdorferi
M297, a strain that has been reported to be non-
infectious at least in hamsters [11]. In addition, we
¢nd multiple kDa Fn-BAs in both pathogenic (low
passage B. turicatae) and non-pathogenic (high pas-
sage B. hermsii) Borrelia species that cause ‘relapsing
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fever’. Because of these ¢ndings, at the present we
cannot make any direct correlation between the pres-
ence of the Fn-BAs and spirochete pathogenicity in
humans.
We hypothesize that B. burgdorferi-associated Fn-
BAs play a role in spirochete interactions with ¢bro-
nectins, collagen, integrins and other related ECM
components. Because of the known interactions of
¢bronectin with collagen and other ECM compo-
nents [1,20^25], we expected that ¢bronectin would
mediate the binding of B. burgdorferi and related
Borrelia species to collagen and/or associated proteo-
glycans. In preliminary experiments we ¢nd that ¢-
bronectin can enhance the adhesion of B. burgdorferi
to puri¢ed human collagen as well as to dextran
sulfate (not shown). The fact that the synthetic pep-
tide RGDS (but not RGD or RFDS peptides) can
mimic this enhancement (at least to collagen) indi-
cates that this event may require the RGDS cell rec-
ognition sequence of ¢bronectin. It is relevant that
others also ¢nd that B. burgdorferi can bind to solu-
ble or immobilized heparin [35^38]. In addition,
Dawson and Ellen [32] have reported that T. denti-
cola binds equally well to coverslips coated with ei-
ther ¢bronectin or RGDS containing peptides, but
not to non-RGDS peptides. It has been documented
that B. burgdorferi binds integrin KIIbL3 [39,40] and
proteins with sequence similarity to an K-subunit of
integrin has been found on the outer sheath of some
strains of T. denticola [41]. The interaction of spiro-
chete-bound ¢bronectin with integrin receptors pre-
sumably leads to rearrangement of the cytoskeletal
structure and signaling responses inside the cell [23^
25,42].
Borrelia burgdorferi binds to many mammalian cell
types including ¢broblasts [7,43,44]. Recently, a nov-
el population of circulating ¢broblast-like cells has
been described. They are called peripheral blood ¢-
brocytes [45]. These cells express both collagen types
I and III and ¢bronectin on their cell surfaces. These
rapidly enter sites of tissue injury as well as target to
connective scar tissue [45]. Since ¢brocytes can se-
crete collagen as well as both recruit and activate
T-cells it is speculated that these cells may play a
critical role in certain connective tissue disorders
[46,47]. Because of the predilection of B. burgdorferi
for collagenous connective tissue [5^7] and ¢bronec-
tin (this paper; [8]) we predicted that the spirochete
would also interact with ¢brocytes. Indeed, we ¢nd
that ¢brocytes are able to bind and internalized B.
burgdorferi [48]. The implications of these ¢ndings
are exciting and far reaching.
In summary, we have demonstrated that B. burg-
dorferi express microbial surface components which
recognize the adhesive matrix molecule ¢bronectin
(¢bronectin-binding MSCRAMMs). We envision a
role for ¢bronectin-binding MSCRAMMs in spiro-
chete cell interactions. These studies are important
for the development of ¢bronectin-binding
MSCRAMM based vaccines capable of blocking
one or more critical steps in normal spirochete^
host interactions.
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